Non-small cell lung cancer (NSCLC) accounts for up to 85% of lung cancer cases in the United States. Somatic mutations in EGFR, KRAS, ALK, and PIK3CA have been identified in a subset of NSCLC. The use of targeted therapies based on defined genetic alterations in these oncogenes has become standard practice in treatment of NSCLC. The most frequently occurring mutations in EGFR (L858R, exon 19 deletions) are associated with sensitivity to EGFR tyrosine kinase inhibitors (TKIs). The T790M gatekeeper mutation has been implicated in acquired resistance to first generation EGFR TKIs, however it confers sensitivity to more recently developed targeted therapies. EGFR mutations are found in up to 15% of Caucasian and 4% of Asian populations. Mutations in KRAS are associated with increased sensitivity to ALK TKIs. PIK3CA mutations are found in less than 5% of lung cancer cases. Although there are currently no approved therapies targeting PIK3CA, mutations in this gene have been found in EGFR-mutated lung tumors with acquired resistance to EGFR TKIs.
Available kits for Lung Cancer are as follows :
|S.No.||Product Name||Catalog Number||Platform|
|1||EGFR Mutation Analysis Kit||EGFR-RT52||For Real-Time PCR|
|2||PIK3CA Mutation Analysis Kit||PI3K-RT48||For Real-Time PCR|
|3||EML4-ALK Fusion Gene Detection Kit||ALKFG-RT46||For Real-Time PCR|
|4||KRAS Mutation Analysis Kit||KRAS-RT50||For Real-Time PCR|
|5||ctDNA EGFR Mutation Detection Kit||CTEGFR-48||For Real Time PCR|
The assessment procedure involves three simple steps:
1) Isolation of DNA or RNA from tumor biopsies, paraffin-embedded sections (FFPE), fresh frozen tumors, or plasma (for cell free kit).
2) Amplification using the provided reagents.
3) Data analysis and interpretation using the real-time PCR software or provided analysis worksheet.
The EGFR, PIK3CA, and KRAS assays require genomic DNA. Mutation detection is based on allele-specific amplification and detection with hydrolysis probes. The EML4-ALK assay requires total RNA input and is based on a one-step cDNA synthesis and quantitative PCR method. The cell-free EGFR assay requires circulating tumor DNA extracted from plasma. Mutation detection is based on allele-specific amplification and detection with hydrolysis probes.
All kits require a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. Additionally, the Cell-Free EGFR Mutation Detection kit requires the capability to detect ROX and CY5 fluorescent probes.
All reagents required for PCR amplification/detection, as well as validated reaction controls, are included. Columns and reagents for DNA or RNA isolation are not included.